At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
In Brief
A Phase 2 clinical trial evaluating Sitagliptin and Placebo for sitagliptin for HIV-1 Infection. Completed, enrolled 90 participants across 16 sites.
Detailed Summary
The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin) reduces inflammation and immune activation markers in HIV-infected men and women when compared to a placebo (inactive medication like a dummy pill). The study evaluated whether taking 100 mg of sitagliptin by mouth daily for 16 weeks is safe and effective for HIV-infected persons on antiretroviral therapy (ART) who do not have diabetes. Sitagliptin is a medication that is used to treat people with diabetes (high blood sugar) but also may reduce inflammation in the body.
Study Details
Timeline
Interventions
100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.